Plasma sPLA2-IIa | < 2.4 ng/ml | > 2.4 ng/ml | Total case# | %Senstivity | %Specificity |
---|---|---|---|---|---|
Table 3a: Determination of plasma sPLA2-IIa to predict lung cancer by ROC analysis. | Â | ||||
BNLCC lung cancer vs. benign SPN | Â | Â | Â | Â | Â |
Benign SPN | 24 | 5 | 29 | Â | 86 |
Lung cancer | 50 | 46 | 96 | 48 | Â |
Stage 1 lung cancer | 24 | 20 | 44 | 45 | Â |
Stage 2 lung cancer | 6 | 12 | 18 | 67 | Â |
GELCC lung cancer vs. benign SPN | Â | Â | Â | Â | Â |
Lung cancer | 16 | 28 | 44 | 64 | Â |
Table 3b: Combined sPLA2-IIa, CEA, and Cyfra21.1 blood tests increase the sentisitivity to predict lung cancer. | |||||
sPLA2-IIa | < 2.4 ng/ml | > 2.4 ng/ml | Â | Â | Â |
CEA | < 6.0 ng/ml | > 6.0 ng/ml | Total case# | %Senstivity | %Specificity |
Cyfra21.1 | < 3.3 ng/ml | > 3.3 ng/ml | Â | Â | Â |
BNLCC lung cancer vs. benign SPN | Â | Â | Â | Â | Â |
Benign SPN | 22 | 7 | 29 | Â | 76 |
Lung cancer | 36 | 60 | 96 | 63 | Â |
Stage 1 lung cancer | 18 | 26 | 44 | 59 | Â |
Stage 2 lung cancer | 5 | 13 | 18 | 72 | Â |
CEA | < 6.0 ng/ml | > 6.0 ng/ml | Total case# | %Senstivity | %Specificity |
BNLCC lung cancer vs. benign SPN | Â | Â | Â | Â | Â |
Benign SPN | 28 | 1 | 29 | Â | 97 |
Lung cancer | 77 | 19 | 96 | 20 | Â |
Cyfra21.1 | < 3.3 ng/ml | > 3.3 ng/ml | Total case# | %Senstivity | %Specificity |
BNLCC lung cancer vs. benign SPN | Â | Â | Â | Â | Â |
Benign SPN | 27 | 2 | 29 | Â | 93 |
Lung cancer | 83 | 13 | 96 | 14 | Â |